Novel Vaccine Adjuvants Based on Cationic Peptide Delivery Systems

Modern Biopharmaceuticals: Design, Development and Optimization

Volumn 4, Issue , 2008, Pages 1419-1443

  Lingnau, Karen ^a   Klade, Christoph ^a   Buschle, Michael ^a   Von Gabain, Alexander ^a  

^a INTERCELL AG   (Austria)

Author keywords

Adjuvants; Chloroquine; Ovalbumin; Poly L arginine; Vaccine

Indexed keywords

EID: 84889954515     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620982.ch58     Document Type: Chapter

References (42)

1. Dennehy, P.H. (2001) Active Immunization in the United States: Developments over the past decade. Clin. Microbiol. Rev. 14, 872-908.
2. Rubin L.G. (2000) Pneumococcal vaccine. Pediatr. Clin. North Am. 47, 269-285.
3. Koelle, D.M. and Lawrence, C. (2003) Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research. Clin. Microbiol. Rev. 16, 96-113.
4. Slovin, S. F., Ragupathi, G., Adluri, S., Ungers, G., Terry, K., Kim, K., Spassova, M., Bornmann, W. G., Fazzari, M., Dantis, L., Olkiewicz, K., Lloyd, K. O., Livingston, P. O., Danishefsky, S. J. and Scher, I.H. (1999) Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. USA 96, 5710-5715.
5. Correa, I. and Plunkett, T. (2001) Update on HER-2 as a target for cancer therapy: HER2/ neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res. 3, 399-403.
6. Malin, D., Alvarado, C. L., Woodhouse, K. S., Karp, H., Urdiales, E., Lay, D., Appleby, P., Moon, W. D., Ennifar, S., Basham, L. and Fattom, A. (2002) Passive Immunization against nicotine attenuates nicotine discrimination. Life Sci. 70, 2793-2798.
7. Gupta, R. K. and Siber, G.R (1995) Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 13, 1263-1276.
8. Schijns, V. E. J. C. (2003) Mechanisms of vaccine adjuvant activity: initiation and regulation of immune response by vaccine adjuvants. Vaccine 21, 829-831.
9. Flarend, R. E., Hem, S. L, White, J. L., Elmore, D., Suckow, M. A., Rudy, A.C. and Dandashli, E. A. (1997) In vivo absorption of aluminiumcontaining vaccine adjuvants using 26Al. Vaccine 15, 1314-1318.
10. Zauner, W., Lingnau, K., Mattner, F. von Gabain, A. and Buschle, M. (2001) Defined synthetic vaccines. Biol. Chem. 382, 581-595.
11. Valensi, J. P., Carlson, J. R. and Van Nest, G. A. (1994) Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol. 153, 4029-4039.
12. Wagner, E., Zenke, M., Cotton, M., Beug, H. and Birnstiel, M.L. (1990) Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. USA 94, 3262-3267.
13. Shen, W. C. and Ryser, H. J. (1978) Conjugation of poly-L-lysine to albumin and horseradish peroxidase: a novel method of enhancing the cellular uptake of proteins. Proc. Natl. Acad. Sci. USA 75, 1872-1876.
14. Shen, W. C. and Ryser H.J. (1981) Poly(L-lysine) has different membrane transport and drug-carrier properties when complexed with heparin. Proc. Natl. Acad. Sci. USA 78, 7589-7593.
15. Buschle, M., Schmidt , W., Zauner, W., Mechtler, K., Trska, B., Kirlappos, H. and Birnstiel, M.L. (1997) Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc. Natl. Acad. Sci. USA 94, 3256-3261.
16. Mattner, F., Fleitmann, J.-K., Lingnau, K., Schmidt, W., Egyed, A., Fritz, J., Zauner, W., Wittmann, B., Gorny, I., Berger, M., Kirlappos, H., Otava, A., Birnstiel, M.L. and Buschle, M. (2002) Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T cell responses against cancer antigens. Cancer Res. 62, 1477-1480.
17. Mitchell, D.J., Kim, D.T., Steinman, L., Fathman, C.G. and Rothbard, J. B. (2000) Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Peptide Res. 56, 318-325.
18. Wender, P. A., Mitchell, D.J., Pattabiraman, K., Pelkey, E.T., Steinman, L. and Rothbard, J. B. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc. Natl. Acad. Sci. USA 97, 13003-13008.
19. Fuchs, S.M. and Raines, R.T. (2004) Pathway for polyarginine entry into mammalian cells. Biochemistry 43, 2438-2444.
20. Buschle, M., Schmidt, W., Berger, M., Schaffner, G., Kurzbauer, R., Killisch, I., Tiedemann, J.-K., Trska, B., Kirlappos, H., Mechtler, K., Schilcher, F., Gabler, C. and M.L. Birnstiel. (1998) Chemically defined, cell-free cancer vaccines: use of tumor antigen-derived peptides or polyepitope proteins for vaccination. Gene Ther. Mol. Biol. 1, 309-322.
21. Schmidt, W., Schweighofer, T., Herbst, E., Maas, G., Berger, M., Schilcher, F., Schaffner, G. and Birnstiel, M.L. (1995) Cancer vaccines: The interleukin 2 dosage effect. Proc. Natl. Acad. Sci. USA 92, 4711-4714.
22. Dye, C., Scheele, S., Dolin, P., Pathania, V., and Raviglione, M.C. (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282, 677-686.
23. Colditz, G. A., Brewer, T.F. , Berkey, C. S., Wilson, M.E., Burdick, E., Fineberg, H.V. and Mosteller, F. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271, 698-702.
24. Zasloff, M. (2002) Antimicrobial peptides of multicellular organisms. Nature 1, 389-395.
25. Van t'Hof, W., Veerman, E. C. I., Helmerhorst, E. J. and Amerongen, A.V. N. (2001) Antimicrobial peptides: properties and applicability. Biol. Chem. 382, 597-619.
26. Yang, D., Biragyn, A., Kwak, L.W. and Oppenheim, J. J. (2002) Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 23, 291-296.
27. Brotz, H., Josten, M., Wiedemann, I., Schneider, U., Gotz, F., Bierbaum, G. and Sahl, H.G. (1998) Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 30, 317-327.
28. Alvarez-Bravo, J., Kurata, S. and Natori, S. (1994) Novel synthetic antimicrobial peptides effective against methicillin-resistant Staphylococcus aureus. Biochem. J. 302, 535-538.
29. Alvarez-Bravo, J., Kurata, S. and Natori, S.(1995) Mode of action of an antibacterial peptide, KLKLLLLLKLK-NH2. Biochem. J. 117, 1312-1316.
30. Nakajima, Y., Alvarez-Bravo, J., Cho, J.-H., Homma, K.-I., Kanegasaki, S. and Natori, S. (1997) Chemotherapeutic activity of synthetic antimicrobial peptides: correlation between chemotherapeutic activity and neutrophil-activating activity. FEBS Lett. 415, 64-66.
31. Cho, J.-H., Homma, K.-I., Kanegasaki, S. and Natori, S. (1999) Activation of human neutrophils by a synthetic anti-microbial peptide, KLKLLLLLKLK-Nh2, via cell surface calreticulin. Eur. J. Chem. 266, 878-885.
32. Fritz, J. H., Brunner, S., Birnstiel, M.L., Buschle, M., Gabain, A., Mattner, F. and Zauner, W. (2004) The antimicrobial peptide KLKLLLLLKLK induces adaptive immunity to co-injected antigens. Vaccine 22, 3274-3284.
33. Takeda, K. and Akira, S. (2004) TLR signaling pathways. Semin. Immunol. 16, 3-9.
34. Takeshita, F., Gursel, I., Ishii, K. J., Suzuki, K., Gursel, M. and Klinman, D.M. (2004) Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin. Immunol. 16, 17-22.
35. Ahmad-Nejad, P., Häcker, H., Rutz, M., Bauer, S., Vabulas, R.M. and Wagner, H. (2002) Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32, 1958-1968.
36. Sparwasser, T., Miethke, T., Lipford, G., Borschert, K., Hacker, H., Heeg, K., Wagner, H. (1997) Bacterial DNA causes septic shock. Nature 386, 336-337.
37. Sparwasser, T., Miethke, T., Lipford, G., Erdmann, A., Hacker, H., Heeg, K., Wagner, H. (1997) Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur. J. Immunol. 27, 1671-1679.
38. Schellack, C., Prinz, K., Egyed, A., Fritz, J., Wittmann, B., Ginzler, M., Swatosch, G., Zauner, W., Kast, C., Akira, S., Gabain, A.V., Buschle, M., Lingnau, K. (submitted) IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses.
39. Manetti, R., Annunziato, F., Tomasevic, L., Gianno, V., Parronchi, P., Romagnani, S. and Maggi, E. (1995) Polyinosinic acid: polycytidylic acid promotes T helper type 1-specific immune responses by stimulating macrophage production of interferon-alpha and interleukin-12. Eur. J. Immunol. 25, 2656-2660.
40. Cella, M., Salio, M., Sakakibara, Y., Langen, H., Julkunen, I. and Lanzavecchia, A. (1999) Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 189, 821-829.
41. Simmler, M. C., Bruley-Rosset, M., Belpomme, D. and Schwarzenberg, L. (1977) Clinical trial of poly I-poly C as an immunity adjuvant and an immunorestoration agent. Eur. J. Cancer 13, 463-467.
42. Guggenheim, M.A. and Baron, S. (1977) Clinical studies of an interferon inducer, polyriboinosinic-polyribocytidylic acid [poly (I)-poly (C)], in children. J. Infect. Dis. 136, 50-58.